enGene Therapeutics Inc. Common Stock (ENGN)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
enGene Therapeutics Inc. Common Stock (ENGN) is listed on Nasdaq, where it has traded since November 1, 2023.
- Listed On
- Nasdaq
- Listed Since
- November 1, 2023
- Employees
- 82
- Market Cap
- $131M
About enGene Therapeutics Inc. Common Stock
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 60 institutions reported holding ENGN, with 50.0 million shares worth $86.5 million in aggregate. The largest reported holder was Fcpm III Services B.V, with 9.6 million shares worth $16.7 million. Of the 5 largest holders listed below, 2 opened new positions in ENGN, 1 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Fcpm III Services B.V | 9,632,561 | $17M | Unchanged |
| Bml Capital Management | 6,669,908 | $12M | New position |
| Siren, | 6,256,662 | $11M | Added 19.1% |
| Perceptive Advisors | 4,822,169 | $8M | Reduced 17.25% |
| Ameriprise Financial | 2,675,876 | $5M | New position |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ENGN?
enGene Therapeutics Inc. Common Stock (ENGN) is listed on Nasdaq, where it has traded since November 1, 2023.
Who are the largest institutional holders of ENGN?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ENGN were Fcpm III Services B.V, Bml Capital Management and Siren,.
How many institutions own ENGN?
60 institutions reported a position in ENGN for the quarter ended June 30, 2026, worth $86.5 million in total.
Did institutions buy or sell ENGN last quarter?
Of the 5 largest reported holders, 2 opened new positions in ENGN, 1 added shares, 1 reduced its position and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for ENGN.
Every reported institutional holder, plus insider and congressional trades in ENGN, on SentiSense.